An approach towards the synthesis of potential metal-chelating TSAO-T derivatives as bidentate inhibitors of human immunodeficiency virus type 1 reverse transcriptase

Antiviral Chemistry and Chemotherapy

Volumn 9, Issue 5, 1998, Pages 413-422

  Chamorro, C ^a   Camarasa, M J ^a   Perez Perez M J ^a   De Clercq, E ^b   Balzarini, J ^b   San Felix A ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

diketones; 3' Spironucleosides; AIDS; Metal chelating; Non nucleoside HIV 1 RT inhibitors; TSAO T

Indexed keywords

ANTIVIRUS AGENT; CHELATING AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS ENZYME;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; VIRUS INHIBITION;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CELL LINE; CHELATING AGENTS; HIV-1; HIV-2; HUMANS; MOLECULAR STRUCTURE; NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS; SPIRO COMPOUNDS; THYMIDINE; VIRUS REPLICATION;

EID: 0031666864     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Althaus IW, Chou JJ, Gonzales AJ, Deibel MR, Chou CK, Kezdy FJ, Romero DL, Aristoff PA, Tarpley WG & Reusser F (1993) Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E. Journal of Biological Chemistry 268:6119-6124.
2. Balzarini J, Pérez-Pérez MJ, San-Félix A, Camarasa MJ, Bathurst IC, Barr PJ & De Clercq E (1992a) Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1 specific nucleoside analogue 2′,5′-bis-O-(t-butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide) thymine (TSAO-T). Journal of Biological Chemistry 267:11831-11838.
3. Balzarini J, Pérez-Pérez MJ, San-Felix A, Schols D, Perno CF, Vandamme AM, Camarasa MJ & De Clercq E (1992b) 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide)pyrimidine (TSAO) nucleoside analogues: highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proceedings of the National Academy of Sciences, USA 89:4392-4396.
4. Balzarini J, Pérez-Pérez MJ, San-Félix A, Velázquez S, Camarasa MJ & De Clercq E (1992c) [2′,5′-bis-O-(tert-butyldimethylsilyl)]-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide) (TSAO) derivatives of purine and pyrimidine nucleosides as potent and selective inhibitors of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 36:1073-1080.
5. Balzarini J, Karlsson A, Pérez-Pérez MJ, Vrang L, Walbers J, Zhang H, Öberg B, Vandamme AM, Camarasa MJ & De Clercq E (1993a) HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology 192:246-253.
6. Balzarini J, Camarasa MJ & Karlsson A (1993b) TSAO derivatives: highly specific human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors. Drugs of the Future 18:1043-1055.
7. Brogden PJ, Gabbutt CD & Hepworth JD (1984) Pyrans and fused pyrans: (i) structure. In Comprehensive Heterocyclic Chemistry vol. 3, pp. 573-645. Edited by AJ Boulton and A McKillop. Oxford: Pergamon Press.
8. Camarasa MJ, Pérez-Pérez MJ, San-Félix A, Balzarini J & De Clercq E (1992) 3′-Spironucleosides (TSAO derivatives), a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of 3′-spiro-5″-[4″-amino-1″,2″-oxathiole-2″, 2″-dioxide]pyrimidine nucleosides. Journal of Medicinal Chemistry 35:2721-2727.
9. Camarasa MJ, Pérez-Pérez MJ, Velázquez S, San-Félix A, Alvarez A, Ingate S, Jimeno ML, Karlsson A, De Clercq E & Balzarini J (1995) TSAO derivatives: highly specific inhibitors of human immunodeficiency virus type-1 (HIV-1) replication. Nucleosides and Nucleotides 14:585-594.
10. Cativiela C, Serrano JL & Zurbano MM (1995) Synthesis of 3-substituted pentane-2,4-diones: valuable intermediates for liquid crystals. Journal of Organic Chemistry 60:3074-3083.
11. Choudhary A & Baumstark AL (1989) Convenient, high-yield method for the methylation of 1,3-diketones. Synthesis 688-690.
12. De Clercq E (1993) HIV-1 specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase. Medicinal Research Reviews 13:229-258.
13. De Clercq E (1996a) What can be expected from non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the treatment of human immunodeficiency virus type 1 (HIV-1) infections? Reviews in Medical Virology 6:97-117.
14. De Clercq E (1996b) Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. Medicinal Research Reviews 16:125-157.
15. Diana GD, Salvador UJ, Zalay ES, Carabateas PM, Williams GL, Collins JC & Pancic F (1977) Antiviral activity of some β-diketones. 2. Aryloxy alkyl diketones. In vitro activity against both RNA and DNA viruses. Journal of Medicinal Chemistry 20:757-761.
16. Diana GD, Carabateas PM, Salvador UJ, Williams GL, Zalay ES, Pancic F, Steinberg BA & Collins JC (1978) Antiviral activity of some β-diketones. 3. Aryl Bis (β-diketones). Antiherpetic activity. Journal of Medicinal Chemistry 21:689-692.
17. D'Incan E & Viout P (1975) Orientation de l'alkylation d'anions ambidents par les sels d'ammonium quaternaire dans les conditions de la catalyse par transfert de phase. Tetrahedron 31:159-164.
18. Ding J, Das K, Moereels H, Koymans L, Andries K, Janssen PAJ, Hughes SH & Arnold E (1995a) Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse non-nucleoside inhibitors. Nature Structural Biology 2:407-415.
19. Ding J, Das K, Tantillo C, Zhang W, Clark ADJ, Jessen S, Lu X, Hsiou Y, Jacobo-Molina A, Andries K, Pauwels R, Moereels H, Koymans L, Janssen PAJ, Smith RHJ, Kroeger Koepke R, Michejda CJ, Hughes SH, Arnold E (1995b) Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R95845 at 2.8 Å resolution. Structure 3:365-379.
20. Frank KB, Noll GJ, Connell EV & Sim IS (1991) Kinetic interaction of human immunodeficiency virus type 1 reverse transcriptase with the antiviral tetrahydroimidazo[4,5,1-jk]-[1,4]-benzodiazepine-2-(1H)-thione compound R82150. Journal of Biological Chemistry 266:14231-14236.
21. Hopkins AL, Ren J, Esnouf RM, Willcox BE, Jones Y, Ross C, Miyasaka T, Walker RT, Tanaka H, Stammers DK & Stuart DI (1996) Complexes of HIV-1 reverse transcriptase with inhibitors of HEPT series reveal conformational changes relevant to the design of potent non-nucleosides inhibitors. Journal of Medicinal Chemistry 39:1589-1600.
22. House HO (1965) The alkylation of active methylene compounds. In Modern Synthetic Reactions, pp. 163-215. Edited by WA Benjamin. New York and Amsterdam: Elsevier.
23. Hutchinson DW (1985) Metal chelators as potential antiviral agents. Antiviral Research 5:193-205.
24. Jackman LM & Lange BC (1977) Structure and reactivity of alkali metal enolates. Tetrahedron 33:2737-2769.
25. Kirmse W & Schnurr O (1977) Pathways from nitrosooxazolidones to vinyl azides. Journal of the Americal Chemical Society 99:3539-3541.
26. Kohlstaedt LA, Wang J, Friedman JM, Rice PA & Steitz TA (1992) Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
27. Kurts AL, Genkina NK, Macias A, Beletskaya IP & Reutov OA (1971) Reactivity of ambident anions. Hardness of alkyl groups and symbiotic effect in alkylation of ambident anions. Tetrahedron 27:4777-4785.
28. Le Noble WJ & Frank Morris H (1969) O vs. C alkylation of ethyl acetoacetate. Journal of Organic Chemistry 6:1969-1973.
29. March J (1985) Delocalized chemical bonding. Tautomerism. In Advanced Organic Chemistry, 3rd edn, pp.66-68 Edited by J March. New York: John Wiley & Sons.
30. Martell & Calvin (1953) Chelate stability constants. In Chemistry of the Metal Chelate Compounds, pp. 514-561. Edited by WM Latimer. New York: Prentice-Hall.
31. Nanni RG, Ding J, Jacobo-Molina A, Hughes SH & Arnold E (1993) Review of HIV-1 reverse transcriptase three-dimensional structure: implications for drug design. Perspectives in Drug Discovery and Design 1:129-150.
32. Pascual C, Meier J & Simon W (1966) Regel zur abschätzung der chemischen verschiebung von protonen an einer doppelbindung. Helvetica Chemica Acta 49:164-168.
33. Pelletier H, Sawaya MA, Kumar A, Wilson SH & Krant J (1994) Structures of ternary complexes of rat DNA polymerase β, a DNA template-primer, and ddCTP. Science 264:1891-1893.
34. Pérez-Pérez MJ, San-Félix A, Balzarini J, De Clercq E & Camarasa MJ (1992) TSAO-analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2′,5′-Bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]- 3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″, 2″-dioxide) pyrimidine and pyrimidine-modified nucleosides. Journal of Medicinal Chemistry 35:2988-2995.
35. Perrin DD (1979) Stability constants of metal-ion complexes: part B organic ligands. In IUPAC Chemical Data Series, number 22, pp. 273-280 and 1019-1020. Edited by DD Perrin. Oxford: Pergamon Press.
36. Ratner L, Haseltine W, Patarca R, Livak KJ, Starcich B, Josephs SF, Doran ER, Rafalski JA, Whitehorn EA, Baumeister K, Ivanoff L, Petteway SR Jr, Pearson ML, Lautenberg JA, Papas TS, Ghrayeb J, Chang NT, Gallo RC & Wong-Staal F (1985) Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313:277-284.
37. Ren JS, Esnouf R, Garman E, Jones Y, Somers D, Ross C, Kirby I, Keeling J, Darby G, Stuart D & Stammers D (1995a) High resolution structure of HIV-1 RT: insights from four RT-inhibitor complexes. Nature Structural Biology 2:293-302.
38. Ren JS, Esnouf R, Hopkins A, Ross C, Jones Y, Stammers D & Stuart D (1995b) The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure 3:915-926.
39. Rosemeyer H & Seele F (1990) Configurational and conformational analysis of regular and modified nucleosides by 1D-NOE difference spectroscopy. Nucleosides and Nucleotides 9:417-418.
40. Smerdon SJ, Jäger J, Wang J, Kohlstaedt LA, Chirino AJ, Friedman JM, Rice PA & Steiz TA (1994) Structure of the binding site for non-nucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences, USA 91:3911-3915.
41. Spence RA, Kati WM, Anderson KS & Johnson KA (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267:988-993.
42. Steitz TA (1993) DNA and RNA-dependent DNA polymerases. Current Opinion in Structural Biology 3:31-38.
43. Velázquez S, Alvarez A, San-Félix A, Jimeno ML, De Clercq E, Balzarini J & Camarasa MJ (1995) Synthesis and anti-HIV-1 activity of [AZT]-[TSAO-T] and [AZT]-[HEPT] dimers as potential multifunctional inhibitors of HIV-1 reverse transcriptase. Journal of Medicinal Chemistry 38:1641-1649.
44. Wu JC, Warren TC, Adams J, Proudfoot J, Skiles J, Raghavan P, Perry C, Potocki I, Farina RR & Grob PM (1991) A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a non-substrate binding site. Biochemistry 30:2022-2026.
45. Young SD (1993) Non-nucleoside inhibitors of HIV-1 reverse transcriptase. Perspectives in Drug Discovery and Design 1:181-192.